Merck Board to Shrink After Member Under Fire Over Conflicts Quits
- Memorial Sloan Kettering CEO Thompson to resign director role
- Drugmaker’s board last week changed rules to keep current CEO
This article is for subscribers only.
Merck & Co. said its board of directors will shrink to 12 members after the resignation of Memorial Sloan Kettering Chief Executive Officer Craig Thompson, who is stepping down following criticism of ties between the hospital’s leaders and health-care companies.
Thompson said he would leave the board of the Kenilworth, New Jersey-based drugmaker, the New York Times and ProPublica reported on Tuesday, after a series of news articles raised questions about relationships between the New York-based cancer center and private industry. Thompson has served as Sloan Kettering’s CEO since 2010. He joined Merck’s board in 2009 and served on the research committee.